BRIEF

on TRANSGENE (EPA:TNG)

Transgene and ProBioGen join forces for personalized cancer vaccines

Stock price chart of TRANSGENE (EPA:TNG) showing fluctuations.

French biotech Transgene and German ProBioGen are partnering to accelerate the development of therapeutic cancer vaccines. The collaboration aims to integrate ProBioGen’s innovative AGE1.CR.pIX® cell line into Transgene’s production of individualized vaccines. Focused on process optimization, this approach is expected to improve manufacturing profitability and efficiency.

AGE1.CR.pIX® is distinguished by its genetic stability and high yield, already proven in Phase III. Transgene hopes to promote individualized medicine, with vaccine solutions specific to each patient. The partnership marks a significant advance in the personalized approach to cancer treatment, offering new perspectives to patients.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all TRANSGENE news